Figg, W.D.

cancer patient irinotecan paclitaxel pharmacokinetic docetaxel clearance genotype treatment cyp 3a polymorphism midazolam allele study variant erythromycin breath test analysis cyp 1b association metabolism erythromycin concentration minute oatp 1b cancer institute tubulin infusion plasma signi slco 1b article polymerization prostate midazolam clearance frequency breath metabolite january -38 sn -38g cyp 1b allele parameter cyp 1b genotype verweij j midazolam clearance test sparreboom effect signi ficantly irinotecan clearance cyp 3a phenotype research survival group american sample estrogen tubulin polymerization sn -38 pharmacol cytochrome 20- minute point irinotecan pharmacokinetics transporter blood prostate cancer table 40 minutes slco 1b gene institute 334 t 4g slco 1b genotype curve caucasian ficant ugt 1a fi rst paclitaxel clearance 14 co 2 probe cer curve